Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification

Area of Science:

• Cardiology
• Pharmacology
• Clinical Diagnostics

Background:

• On-treatment platelet reactivity (OTR) predicts clinical outcomes in patients on thienopyridine therapy.
• Thienopyridines, such as clopidogrel and prasugrel, are crucial antiplatelet agents.
• Understanding OTR is vital for managing patients undergoing procedures like surgery.

Purpose of the Study:

• To evaluate the efficacy of point-of-care platelet reactivity testing in distinguishing patients who have received thienopyridine therapy.
• To establish a diagnostic threshold for detecting thienopyridine drug effect using VerifyNow P2Y12 assay.

Main Methods:

• A randomized, multicenter pharmacodynamic trial involving 54 coronary artery disease patients on aspirin.
• Participants were assigned clopidogrel (75 mg/day) or prasugrel (10 mg/day) for 7 days.
• Platelet reactivity was measured using the VerifyNow P2Y12 test pre-dose and 24 hours post-final dose; receiver operating characteristic (ROC) curve analysis identified optimal cut-offs.

Main Results:

• The VerifyNow P2Y12 test demonstrated high accuracy (c-statistic=0.93, P<0.001) in identifying thienopyridine treatment.
• An optimal cut-off of <213 P2Y12 reaction units (PRU) showed 80% sensitivity and 98% specificity for detecting any thienopyridine effect.
• This threshold exhibited high specificity for clopidogrel (100%) and prasugrel (96%), with varying sensitivities (58% for clopidogrel, 100% for prasugrel).

Conclusions:

• On-treatment platelet reactivity <213 PRU is a highly specific indicator of clopidogrel or prasugrel exposure.
• This finding can aid in managing thienopyridine-treated patients requiring surgery.
• The established diagnostic cut-off aligns with OTR levels linked to ischemic events, supporting the mechanistic link between drug effect and clinical outcomes.